Lisocabtagene Maraleucel Expands the Therapeutic Landscape for Relapsed/Refractory Non-Hodgkin LymphomaByEve Hughes, PharmD,Jordan D. Scott, PharmDFebruary 27th 2025This CAR T-cell therapy has revolutionized the management of high-risk and relapsed or refractory disease.